- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02394743
Correlation Between Estimated Glomerular Filtration Rate(eGFR) and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)
Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. Renal insufficiency is close correlation with atherosclerosis and cardiovascular mortality.
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.Therefore, the purpose of the study is to demonstrate the correlation between eGFR and vascular inflammation detected by 18F FDG-PET.
Study Overview
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
VD
-
Seoul, VD, Korea, Republic of
- Department of Internal Medicine, Korea University College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- absence of prior cancer diagnosis or remission from cancer at the time of PET imaging and throughout the follow-up period;
- >=30 years of age;
- no prior history of cardiovascular disease ; and
- absence of acute or chronic inflammatory or autoimmune disease (based on documented medical history) or use of chronic anti-inflammatory therapy.
Exclusion Criteria:
- age <35 years
- presence of chronic inflammatory disease
- use of anti-inflammatory medications
- presence of active malignant cancer (defined as any radiological or pathological evidence of malignant cancer disease or undergoing chemotherapy or radiation therapy within 1 year before initial PET/CT and throughout the inter-scan duration).
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
eGFR > 90
group whose eGFR is more than 90
|
|
60 < eGFR <90
group whose eGFR is between 60 and 90
|
|
eGFR < 60
group whose eGFR is less than 60
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Correlation between vascular inflammatory status measured by 18F FDG-PET and eGFR by Modification of Diet in Renal Disease(MDRD) formula
Time Frame: at 1 day of taking 18F FDG - PET
|
at 1 day of taking 18F FDG - PET
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PET_eGRF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
Clinical Trials on 18FDG-PET
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Azienda ULSS 12 Veneziana and other collaboratorsActive, not recruiting
-
University Hospital, CaenUnknownAmyotrophic Lateral SclerosisFrance
-
Mayo ClinicCompleted
-
Radboud University Medical CenterDutch Cancer SocietyRecruitingSalivary Gland Cancer | Salivary Duct CarcinomaNetherlands
-
Centre Antoine LacassagneRecruitingNon-Small Cell Bronchopulmonary Carcinoma or MelanomaFrance
-
University of LiegeRecruitingKidney Transplant Rejection | Kidney Transplant; ComplicationsBelgium
-
Catholic University of the Sacred HeartUnknown
-
Centre Hospitalier Universitaire de NiceRecruitingRefractory or Relapsed Non-Hodgkin's LymphomaFrance
-
University Hospital, BordeauxCompletedEndocarditis | Infections of the Implanted MaterialFrance
-
Centre Hospitalier Universitaire DijonNot yet recruiting